Related Experiment Video

Updated: Apr 15, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K

New insights in the management of chronic hepatitis B

Upkar S Gill1, Patrick Tf Kennedy2

  • 1Centre for Immunology and Infectious Diseases, Blizard Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK;

Clinical Medicine (London, England)
|April 1, 2015
PubMed

Insights

Chronic hepatitis B (CHB) is a major global health issue. New treatments aim to achieve HBsAg loss, the gold standard for cure, by addressing unmet needs in disease management and novel therapies.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Chronic hepatitis B (CHB) causes significant mortality (approx. 600,000 deaths/year) due to cirrhosis and hepatocellular carcinoma.
  • The persistence of covalently closed circular DNA (cccDNA) in hepatocytes drives HBV chronicity.
  • Quantitative hepatitis B surface antigen (qHBsAg) serves as a surrogate marker for cccDNA levels and treatment response.

Purpose of the Study:

  • To review unmet needs in CHB management.
  • To discuss strategies for optimizing current therapies.
  • To explore the development of novel agents targeting HBsAg loss.

Main Methods:

  • Review of current literature on CHB pathogenesis and treatment.
  • Analysis of the role of qHBsAg as a biomarker.
  • Discussion of therapeutic goals and future directions.

Main Results:

  • Current antiviral therapies are insufficient for achieving HBsAg loss.
  • HBsAg loss is the defined goal for effective CHB treatment.
  • Better definition of disease phases and intervention timing are needed.

Conclusions:

  • Achieving HBsAg loss requires addressing current therapeutic limitations.
  • Novel antiviral strategies are essential for CHB cure.
  • Optimizing treatment and developing new agents are critical for improving patient outcomes.

Keywords:
HCCcccDNAdisease phaseliver biopsynucleos(t)ide analoguespegylated interferonquantitative HBsAgtransient elastography

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.1K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
63
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
532
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
358
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
820
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
263
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
369